Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTLA in patients with pancreatic adenocarcinoma

Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTLA in patients with pancreatic adenocarcinoma

PDAC is one of the most heterogeneous cancers with low chemotherapeutic sensitivity due to a dense stroma, a weak vasculature and significant biological aggressivity. In cancer, suppressive immune checkpoints are often hyper-activated to ensure an effective evasion of tumor cells from immune surveil...

Full description

Bibliographic Details
Main Authors:	Benjamin Bian, Daniele Fanale, Nelson Dusetti, Julie Roque, Sonia Pastor, Anne-Sophie Chretien, Lorena Incorvaia, Antonio Russo, Daniel Olive, Juan Iovanna
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2019-04-01
Series:	OncoImmunology
Subjects:	immune checkpoint pancreatic cancer outcome butyrophilin 3a programmed cell death-1 programmed cell death ligand-1 b and t lymphocyte attenuator
Online Access:	http://dx.doi.org/10.1080/2162402X.2018.1561120

Similar Items

Prognostic Role of Plasma PD-1, PD-L1, pan-BTN3As and BTN3A1 in Patients Affected by Metastatic Gastrointestinal Stromal Tumors: Can Immune Checkpoints Act as a Sentinel for Short-Term Survival?
by: Daniele Fanale, et al.
Published: (2021-04-01)

New Insights Into the Regulation of γδ T Cells by BTN3A and Other BTN/BTNL in Tumor Immunity
by: Juan-Luis Blazquez, et al.
Published: (2018-07-01)

Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions
by: Lorena Incorvaia, et al.
Published: (2020-01-01)

Soluble BTN2A1 Is a Potential Prognosis Biomarker in Pre-Treated Advanced Renal Cell Carcinoma
by: Emilien Billon, et al.
Published: (2021-04-01)

PD-L1 Expression and Combined Status of PD-L1/PD-1–Positive Tumor Infiltrating Mononuclear Cell Density Predict Prognosis in Glioblastoma Patients
by: Jiheun Han, et al.
Published: (2017-01-01)

Allelic diversity of butyrophilin (BTN1A1) gene in Indian bovines
by: Manoj Kumar, et al.
Published: (2018-02-01)

Downregulation of Immunosuppressive Molecules, PD-1 and PD-L1 but not PD-L2, in the Patients with Multiple Sclerosis
by: Mohammad Reza Javan, et al.
Published: (2016-08-01)

Regulation of Human γδ T Cells by BTN3A1 Protein Stability and ATP-Binding Cassette Transporters
by: David A. Rhodes, et al.
Published: (2018-04-01)

Analysis of the Correlation between Molecular Structural Differences of PD-1/PD-L1 Inhibitors and Adverse Events
by: Tongji XIE, et al.
Published: (2020-07-01)

Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer
by: Maureen L. Drakes, et al.
Published: (2018-05-01)

Progress of PD-1/PD-L1 Inhibitors in Non-small Cell Lung Cancer
by: Zhansheng JIANG, et al.
Published: (2017-02-01)

The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy
by: Antje Tunger, et al.
Published: (2019-09-01)

BTLA Expression in Stage I–III Non–Small-Cell Lung Cancer and Its Correlation with PD-1/PD-L1 and Clinical Outcomes
by: Li X, et al.
Published: (2020-01-01)

PD-1/PD-L1 Axis as a Potential Therapeutic Target for Multiple Sclerosis: A T Cell Perspective
by: HaiXia Li, et al.
Published: (2021-07-01)

Inhibitors of the PD-1/PD-L1 axis for the treatment of head and neck cancer: current status and future perspectives
by: Ran X, et al.
Published: (2017-07-01)

The relationship between the PD-1/PD-L1 pathway and DNA mismatch repair in cervical cancer and its clinical significance
by: Feng YC, et al.
Published: (2018-01-01)

Expression of PD-1 Molecule on Regulatory T Lymphocytes in Patients with Insulin-Dependent Diabetes Mellitus
by: Valentina Perri, et al.
Published: (2015-09-01)

D-1 / PD-L1 EXPRESSION IN INVASIVE BREAST CARCINOMA / CANCER
by: Sammeen Salim, et al.
Published: (2021-02-01)

PD-1/PD-L1 Inhibitors in Cervical Cancer
by: Yuncong Liu, et al.
Published: (2019-02-01)

Sequential Blockade of PD-1 and PD-L1 Causes Fulminant Cardiotoxicity—From Case Report to Mouse Model Validation
by: Shin-Yi Liu, et al.
Published: (2019-04-01)

Management of Adverse Events in Cancer Patients Treated With PD-1/PD-L1 Blockade: Focus on Asian Populations
by: Jiqiao Yang, et al.
Published: (2019-07-01)

Defects in Macrophage Reprogramming in Cancer Therapy: The Negative Impact of PD-L1/PD-1
by: Hao Cai, et al.
Published: (2021-06-01)

Peripheral blood T lymphocytes are downregulated by the PD-1/PD-L1 axis in advanced gastric cancer
by: Witold Zgodzinski, et al.
Published: (2018-04-01)

GLUT1 as a Prognostic Factor for Classical Hodgkin’s Lymphoma: Correlation with PD-L1 and PD-L2 Expression
by: Young Wha Koh, et al.
Published: (2017-03-01)

PD-1/PD-L1 expression in a series of intracranial germinoma and its association with Foxp3+ and CD8+ infiltrating lymphocytes
by: Liu, Bin
Published: (2018)

PD-1/ PD-L1 blockade as a novel treatment for colorectal cancer
by: Neda Yaghoubi, et al.
Published: (2019-02-01)

PD-1 Ligand Expression in Epithelial Thyroid Cancers: Potential Clinical Implications
by: Salvatore Ulisse, et al.
Published: (2019-03-01)

ABCA1, apoA-I, and BTN3A1: A Legitimate Ménage à Trois in Dendritic Cells
by: Chiara Riganti, et al.
Published: (2018-06-01)

Anti-programmed death ligand 1 (PD-L1) inhibitors in metastatic gastric cancer
by: Jang Ho Cho, et al.
Published: (2017-12-01)

Progress on PD-1/PD-L1 Checkpoint Inhibitors in Lung Cancer
by: Di ZHANG, et al.
Published: (2019-06-01)

PD-L1/PD-1 Pattern of Expression Within the Bone Marrow Immune Microenvironment in Smoldering Myeloma and Active Multiple Myeloma Patients
by: Federica Costa, et al.
Published: (2021-01-01)

Expression and Clinical Significance of PD-1 and PD-L1 in Pulmonary Carcinoids
by: Mingbiao LI, et al.
Published: (2016-12-01)

Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon?
by: Luisa Chocarro de Erauso, et al.
Published: (2020-04-01)

PD-1 and PD-L1 are more highly expressed in high-grade bladder cancer than in low-grade cases: PD-L1 might function as a mediator of stage progression in bladder cancer
by: Takashi Kawahara, et al.
Published: (2018-11-01)

The Combination Options and Predictive Biomarkers of PD-1/PD-L1 Inhibitors in Esophageal Cancer
by: Hui Yang, et al.
Published: (2020-03-01)

Immune Monitoring of Cancer Patients Prior to and During CTLA-4 or PD-1/PD-L1 Inhibitor Treatment
by: Antje Tunger, et al.
Published: (2018-03-01)

PD-1/PD-L1 inhibitor therapy: transitioning from a second-line to a first-line therapy for non-small cell lung cancer
by: Jong-Mu Sun
Published: (2017-03-01)

Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer
by: Stephan Kruger, et al.
Published: (2017-05-01)

Clinical and pathological significance of programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) expression in high grade serous ovarian cancer
by: Yılmaz Baş, et al.
Published: (2021-02-01)

The Roles of microRNAs in Regulating the Expression of PD-1/PD-L1 Immune Checkpoint
by: Qingshui Wang, et al.
Published: (2017-11-01)

Cannot write session to /tmp/vufind_sessions/sess_qgj3u3pj4a35lb76fom1782uvj